###begin article-title 0
Integrated associations of genotypes with multiple blood biomarkers linked to coronary heart disease risk
###end article-title 0
###begin p 1
###xml 0 16 0 16 <!--CREATIVE COMMONS-->
CREATIVE COMMONSThis is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License () which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin p 2
###xml 693 694 693 694 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 736 737 736 737 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 748 752 748 752 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;140</sup>
###xml 757 759 757 759 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F7</italic>
###xml 936 940 936 940 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 942 946 942 946 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CETP</italic>
###xml 948 951 948 951 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LPL</italic>
###xml 953 957 953 957 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOB</italic>
###xml 962 966 962 966 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LDLR</italic>
###xml 1022 1024 1022 1024 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F7</italic>
###xml 1026 1029 1026 1029 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CRP</italic>
###xml 1034 1037 1034 1037 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FBB</italic>
###xml 403 406 <span type="species:ncbi:9606">men</span>
Individuals at risk of coronary heart disease (CHD) show multiple correlations across blood biomarkers. Single nucleotide polymorphisms (SNPs) indexing biomarker differences could help distinguish causal from confounded associations because of their random allocation prior to disease. We examined the association of 948 SNPs in 122 candidate genes with 12 CHD-associated phenotypes in 2775 middle aged men (a genic scan). Of these, 140 SNPs indexed differences in HDL- and LDL-cholesterol, triglycerides, C-reactive protein, fibrinogen, factor VII, apolipoproteins AI and B, lipoprotein-associated phospholipase A2, homocysteine or folate, some with large effect sizes and highly significant P-values (e.g. 2.15 standard deviations at P = 9.2 x 10-140 for F7 rs6046 and FVII levels). Top ranking SNPs were then tested for association with additional biomarkers correlated with the index phenotype (phenome scan). Several SNPs (e.g. in APOE, CETP, LPL, APOB and LDLR) influenced multiple phenotypes, while others (e.g. in F7, CRP and FBB) showed restricted association to the index marker. SNPs influencing six blood proteins were used to evaluate the nature of the associations between correlated blood proteins utilizing Mendelian randomization. Multiple SNPs were associated with CHD-related quantitative traits, with some associations restricted to a single marker and others exerting a wider genetic 'footprint'. SNPs indexing biomarkers provide new tools for investigating biological relationships and causal links with disease. Broader and deeper integrated analyses, linking genomic with transcriptomic, proteomic and metabolomic analysis, as well as clinical events could, in principle, better delineate CHD causing pathways amenable to treatment.
###end p 2
###begin title 3
INTRODUCTION
###end title 3
###begin p 4
###xml 237 238 237 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP159C1">1</xref>
###xml 348 349 348 349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP159C2">2</xref>
###xml 786 787 786 787 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP159C3">3</xref>
###xml 1299 1300 1299 1300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP159C4">4</xref>
Like many common disorders, coronary heart disease (CHD) results from a complex interplay between environmental and genetic factors, complicating the identification of the causal pathways, and delaying the development of new treatments (1). By 1981, over 200 phenotypic and other differences had been shown in those with, or at higher risk of CHD (2). Alterations in circulating blood phenotypes (also referred to as biomarkers) such as lipid and lipoprotein particles, proteins involved in inflammation and coagulation, as well as metabolites and markers of oxidant stress, tend to cluster among those at higher risk, making it difficult to ascertain the nature and direction of biological relationships between biomarkers, and the independent effect of any one biomarker on CHD risk (3). These associations may be causal, but alternatively could arise because they mark subclinical disease (reverse causation), other causal factors (confounding) or some combination of the two. Thus far it has only been possible to establish unequivocally a causal role in CHD for one blood phenotype (LDL-cholesterol). This was achieved in large part by developing the HMG-CoA reductase inhibitor (statin) class of drugs that reduce blood level of LDL-cholesterol and testing their effects in randomized trials (4). However, the expense and risk associated with the development of the many selective drugs needed to target the vast array of blood phenotypes implicated in CHD, currently precludes a comprehensive and systematic approach to understanding their causal relevance and limits translation of the basic science and epidemiological findings into new treatments.
###end p 4
###begin p 5
###xml 259 260 259 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP159C5">5</xref>
###xml 261 262 261 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP159C8">8</xref>
###xml 1425 1426 1425 1426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP159C9">9</xref>
###xml 1427 1429 1427 1429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP159C10">10</xref>
Many (if not all) of the circulating biomarkers associated with CHD behave as heritable quantitative traits, and common single nucleotide polymorphisms (SNPs) influencing their variance are now being identified both by candidate gene and genome wide studies (5-8). Unlike the associations between biomarkers, or the association of biomarkers with CHD risk, genetic associations should be protected from reverse causation because genotype is an invariant characteristic, such that there is a unidirectional flow of information from common genome variation to mRNA to protein to complex phenotype and disease. Moreover, since genotype is determined at random at conception, for SNPs affecting CHD risk, intermediate phenotypes (such as blood markers), residing off the causal pathway from SNP to disease, should be balanced evenly among the different genotypic groups, as they are in a randomized clinical trial, whereas biomarkers that mediate the effect of genomic variation on disease risks should differ by genotype. We hypothesized that SNPs, which affect the variance in biomarkers linked to CHD, could be used as unbiased tools with which to understand their causal relevance and to explore the extent to which correlation between multiple CHD-associated phenotypes are affected by confounding. This principle of Mendelian randomization has been applied to assess the causal role of individual biomarkers with CHD risk (9,10). Here we applied Mendelian randomization to help distinguish causal from confounded links between multiple biomarkers.
###end p 5
###begin p 6
###xml 172 173 172 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP159C5">5</xref>
###xml 174 175 174 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP159C7">7</xref>
###xml 532 534 532 534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP159C11">11</xref>
###xml 535 537 535 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP159C13">13</xref>
Formerly, association studies in the cardiovascular genetics field typed SNPs in a single gene or locus of interest. More recently, genome wide association studies (GWAS) (5-7) have extended the breadth of genetic information, but the focus of these studies has been on a single continuous trait or disease outcome, limiting the ability to address inter-relationships among traits. We utilized a genotyping strategy that exploits the recent finding that gene variants regulating expression commonly reside in the vicinity of genes (11-13), to build a panel of SNPs influencing variance in one or more CHD-related biomarkers to investigate the nature of the association between markers.
###end p 6
###begin title 7
RESULTS
###end title 7
###begin title 8
Between-phenotype correlations and associations with CHD risk
###end title 8
###begin p 9
###xml 687 688 687 688 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP159F1">1</xref>
###xml 826 827 826 827 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 873 874 871 872 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 955 956 951 952 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 965 967 961 963 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;8</sup>
###xml 1069 1070 1065 1066 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 75 78 <span type="species:ncbi:9606">men</span>
###xml 494 497 <span type="species:ncbi:9606">Men</span>
In the prospective Northwick Park Heart Study II of 3102 initially healthy men followed prospectively for a median of 13.6 years, there were 296 definite fatal or non-fatal CHD events. Measures of 14 intermediate phenotypes were available, six with annual repeat measures (on six occasions) and single measures for the remaining eight (). To delineate the potential for confounding in the associations of blood markers and other phenotypes with CHD, we assessed between-phenotype correlations. Men who developed a CHD event on follow-up exhibited multiple phenotypes which distinguished them from those who remained disease free, and these differences were highly inter-correlated (Fig. 1 and ). Seventy-two of the 105 possible pair-wise correlations between blood markers and other CHD-related traits were significant with a P-value </= 0.05 (68 traits significant with a P-value </= 0.01), which significantly exceeds the five expected by chance alone (P < 1 x 10-8 for observed versus the expected). Many of the associations were highly significant and the absolute P-values are provided in .
###end p 9
###begin p 10
###xml 149 150 149 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">R</italic>
###xml 153 154 153 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 165 166 165 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 63 66 <span type="species:ncbi:9606">men</span>
Correlations between multiple phenotypes linked to CHD in 2775 men from the NPHSII study. Values in cells indicate Pearson's correlation coefficient R. *P < 0.01, **P < 0.001 (see colour code). Baseline and five repeat measures were available for cholesterol, triglycerides (TG), coagulation factor VII (FVIIc), fibrinogen, blood pressure (BP), smoking and body mass index (BMI) and single measures for the remaining traits.
###end p 10
###begin title 11
Genic scan
###end title 11
###begin p 12
###xml 277 309 277 309 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOB, LDLR, PCSK9, APOE-C1-C2-C4</italic>
###xml 314 318 314 318 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRP5</italic>
###xml 354 379 354 379 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOB, LDLR, APOE-C1-C2-C4</italic>
###xml 381 387 381 387 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PLA2G7</italic>
###xml 389 410 389 410 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9, CDKN, EXT2, C3</italic>
###xml 415 420 415 420 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GSTM3</italic>
###xml 456 490 456 490 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CETP, ALOX5AP APOA5-A4-C3-A1, LIPC</italic>
###xml 495 498 495 498 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LPL</italic>
###xml 542 644 542 644 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LPL, APOA5-A4-C3-A1, TGFB1, PECAM, IL6R, C2, ILRN1, INS, LDLR, F7, ANGPTL4, APOB, GCKR, IL18RAP, PCSK9</italic>
###xml 649 653 649 653 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRP5</italic>
###xml 709 769 709 769 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LIPC, CETP, ALOX5AP, APOA5-A4-C3-A1, APOE-C1-C2-C4, IGF2, C3</italic>
###xml 774 777 774 777 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LPL</italic>
###xml 873 916 873 916 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE-C1-C2-C4, APOB, LDLR, PCSK9, LPL GSTM4</italic>
###xml 921 925 921 925 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EXT2</italic>
###xml 941 954 941 954 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE-C1-C2-C4</italic>
###xml 959 963 959 963 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NOS3</italic>
###xml 1021 1023 1021 1023 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F7</italic>
###xml 1047 1052 1047 1052 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PROCR</italic>
###xml 1146 1154 1146 1154 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FIBA-B-G</italic>
###xml 1164 1168 1164 1168 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UCP3</italic>
###xml 1170 1175 1170 1175 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GSTM4</italic>
###xml 1184 1198 1184 1198 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOA5-A4-C3-A1</italic>
###xml 1266 1279 1266 1279 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE-C1-C2-C4</italic>
###xml 1284 1287 1284 1287 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CRP</italic>
###xml 1446 1447 1446 1447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP159F2">2</xref>
###xml 1898 1900 1898 1900 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP159C14">14</xref>
We genotyped 948 SNPs in 122 genes chosen for a high prior probability of association with CHD-associated phenotypes in NPHS II based on prior association studies and biological evidence. A total of 134 SNP-trait associations were identified distributed as follows: 12 SNPs in APOB, LDLR, PCSK9, APOE-C1-C2-C4 and LRP5 with total cholesterol; 23 SNPs in APOB, LDLR, APOE-C1-C2-C4, PLA2G7, PCSK9, CDKN, EXT2, C3 and GSTM3 with LDL-cholesterol and 6 SNPs in CETP, ALOX5AP APOA5-A4-C3-A1, LIPC and LPL with HDL cholesterol. Thirty-seven SNPs in LPL, APOA5-A4-C3-A1, TGFB1, PECAM, IL6R, C2, ILRN1, INS, LDLR, F7, ANGPTL4, APOB, GCKR, IL18RAP, PCSK9 and LRP5 were associated with triglyceride levels. Nine SNPs in LIPC, CETP, ALOX5AP, APOA5-A4-C3-A1, APOE-C1-C2-C4, IGF2, C3 and LPL were associated with apoAI levels. Twelve SNPs were associated with apoB levels; these were in APOE-C1-C2-C4, APOB, LDLR, PCSK9, LPL GSTM4 and EXT2. Three SNPs in APOE-C1-C2-C4 and NOS3 were associated with Lp-PLA2 activity. Seven SNPs in the F7 gene itself and one in PROCR exhibited very highly significant association with blood factor VII level. Seven SNPs in the FIBA-B-G cluster, UCP3, GSTM4 and the APOA5-A4-C3-A1 cluster were associated with fibrinogen. Five SNPs from two genes, APOE-C1-C2-C4 and CRP, were associated with C-reactive protein. These represented 98 unique SNPs in 36 genes. The full range of SNP-phenotype associations is illustrated in Figure 2A-l and summarized in . Because of the gene-centric strategy, the SNP-phenotype associations clustered within genes, even though SNPs had been chosen as tag SNPs. These associations remained significant even after the LD structure between them was considered (see ). Thus, for some genes, several SNPs remain associated with the blood biomarker, supporting the possibility of independent associations at a given locus, as we noted previously for CRP (14).
###end p 12
###begin p 13
###xml 158 159 158 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 170 172 170 172 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;3</sup>
Associations of 860 SNPs by chromosome with 12 blood phenotypes. The horizontal line indicates a critical FDR threshold of 0.2, approximately equivalent to a P-value < 10-3.
###end p 13
###begin title 14
Significance and validity of the genetic associations
###end title 14
###begin p 15
###xml 153 154 153 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 165 167 165 167 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;7</sup>
###xml 285 286 285 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="DDP159TB1">1</xref>
###xml 312 316 312 316 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LDLR</italic>
###xml 318 319 318 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP159C5">5</xref>
###xml 320 322 320 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP159C15">15</xref>
###xml 361 365 361 365 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 392 393 392 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP159C5">5</xref>
###xml 394 395 394 395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP159C6">6</xref>
###xml 421 425 421 425 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CETP</italic>
###xml 448 449 448 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP159C5">5</xref>
###xml 450 451 450 451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP159C6">6</xref>
###xml 452 454 452 454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP159C15">15</xref>
Despite the moderate size of the data set, nearly 13% (18 of 140) of the associations achieved the level of significance conventionally applied to GWAS (P-value < 10-7). Sixteen of the 134 SNPs were also directly typed and were significant hits in recent GWASs of blood markers (Table 1) including: rs6511720 in LDLR (5,15), SNPs in LD with rs42935/rs7412 with APOE SNPs and LDL-cholesterol (5,6); as well as rs708272 in CETP with HDL-cholesterol (5,6,15).
###end p 15
###begin p 16
SNPs from the current study showing replication with GWAS hits
###end p 16
###begin p 17
The phenotype associated with the SNP from the GWAS, if different from the current study is given in brackets.
###end p 17
###begin p 18
LDL, low density lipoprotein; TG, triglycerides; AD, Alzheimer's disease, CRP, C-reactive protein, HDL, high density lipoprotein.
###end p 18
###begin p 19
###xml 91 94 91 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cis</italic>
###xml 220 221 220 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 249 251 249 251 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;4</sup>
###xml 258 260 258 260 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;7</sup>
###xml 282 286 282 286 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;140</sup>
###xml 301 303 301 303 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F7</italic>
###xml 432 433 432 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP159C8">8</xref>
Notably, for each genic scan where the outcome was a single-protein phenotype at least one cis-acting SNP in the gene encoding the cognate protein was always identified among the most significantly associated SNPs, with P-values generally between 10-4 and 10-7, but as extreme as 10-140 for rs6046 in F7 and blood factor VII levels. In line with a recent report, we refer to these genes as protein quantitative trait genes (pQTGs) (8) and the SNPs as pQTSNPs.
###end p 19
###begin title 20
Effect size
###end title 20
###begin p 21
###xml 231 232 231 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP159F3">3</xref>
###xml 426 428 426 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F7</italic>
###xml 504 505 492 493 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP159F3">3</xref>
###xml 1064 1066 1052 1054 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F7</italic>
###xml 1073 1074 1061 1062 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP159F3">3</xref>
The effect of each associating SNP was expressed both in terms of the proportion of the trait variance explained, and as the standardized mean difference in trait level between subjects homozygous for the alternative alleles (Fig. 3A and B), allowing effect sizes to be expressed on a common scale. When considered solely in terms of the variance, the effect size for individual SNPs appeared modest with only two SNPs in the F7 gene, each explaining approximately20% of the variance of factor VII (Fig. 3A), both independently significant of each other. However, for 28 SNPs (24%) crossing the FDR threshold, the difference in average trait values between homozygous subjects exceeded 0.5 standard deviations (SD) of the population distribution, with the difference exceeding 0.75 SD for 17 SNPs. For 10 SNPs, the difference in trait values between homozygous subjects exceeded 1 SD, with the most extreme differences for a common allele (>5%) being 2.15 SD for the difference in Factor VII levels between subjects homozygous for alternative alleles of rs6046 in F7 (Fig. 3C).
###end p 21
###begin p 22
###xml 169 170 169 170 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 186 187 186 187 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 266 267 266 267 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
The relationship between minor allele frequency and effect size for SNP-phenotype associations exceeding the pre-specified FDR threshold. Effect size was expressed as: (A) variance and (B) as the standardized mean difference for comparisons of homozygous subjects. (C) Examples of SNPs with extreme effects assessed in terms of standardized mean difference.
###end p 22
###begin title 23
Phenome scan
###end title 23
###begin p 24
###xml 156 157 156 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP159F4">4</xref>
###xml 364 394 364 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">intermediate trait of interest</italic>
###xml 516 532 516 532 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">gene of interest</italic>
###xml 835 836 835 836 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">R</italic>
###xml 836 837 836 837 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1238 1239 1238 1239 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 551 558 <span type="species:ncbi:301928">ellipse</span>
We next assessed the association of top ranking genes from the genic scan with additional phenotypes and the findings are illustrated graphically in Figure 4A-H by means of phenome plots. The phenome scan examines the relationship between variants of the gene of interest and all the intermediate traits studied. This is in contrast with the genic scan where each intermediate trait of interest is considered and all the genetic variants associated with it are examined as a Manhattan plot. In the phenome scan, the gene of interest is depicted as an ellipse and the associated phenotypic traits as circles radiating out from it. The circle diameter of each phenotype is a measure of the variance of the phenotype explained by the variation encompassing all SNPs in that gene of interest, with the value (coefficient of determination, R2) given alongside the relevant circle. In addition, for each phenotype, the distance from the gene is a measure of the significance value, adjusted for multiple testing using the false discovery rate (FDR), for the SNP with the strongest signal within the gene of interest. In the phenome scan, we applied a more stringent significance threshold, focusing on those phenotypes crossing an FDR adjusted P-value of <0.1. An inner square of dotted lines has been drawn at this threshold with the gene of interest and the phenotype(s) with FDRs <0.1 being shown in the enlarged subpanel.
###end p 24
###begin p 25
###xml 221 222 221 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">R</italic>
###xml 222 223 222 223 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 366 367 366 367 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">R</italic>
###xml 367 368 367 368 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 712 713 712 713 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1089 1090 1089 1090 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 54 61 <span type="species:ncbi:301928">ellipse</span>
###xml 750 757 <span type="species:ncbi:301928">ellipse</span>
Phenome plots. The gene of interest is depicted as an ellipse and the associated phenotypes traits as circles. The circle diameter is a measure of the variance of the phenotype explained by the variance of the genotypes (R2) of all the SNPs in the gene of interest. The numbers given next to each phenotype are the percent values of the coefficient of determination R2 of the phenotype for the combined effect of all the SNPs of the gene. The distance from the gene to each phenotype is a measure of the significance value, adjusted for multiple testing using the FDR, for the SNP with the strongest signal within the gene of interest. The number shown next to each edge is the percent value of the FDR adjusted P-value with its length measured from ellipse (gene) centre to circle (phenotype) centre. The dashed line represents those phenotypes which fall within the <0.1 FDR with the gene of interest. Those phenotypes and the gene are then expanded alongside in the accompanying figure so that details can be seen more clearly. For the phenome scan, an even more stringent FDR adjusted P-value of <0.1 to reduce further the risk of false-positive association. (Hcy, homocysteine; Flt, folate; SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index).
###end p 25
###begin p 26
###xml 31 33 31 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F7</italic>
###xml 35 38 35 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CRP</italic>
###xml 47 55 47 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FIBA-B-G</italic>
###xml 326 327 326 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP159F1">1</xref>
SNPs in certain pQTGs (e.g. in F7, CRP and the FIBA-B-G cluster) exhibited phenotypic effects that were restricted to an alteration only in the cognate gene product. The restricted nature of the SNP effects for these genes contrasted sharply with the extensive direct phenotypic associations of the proteins they encode (Fig. 1).
###end p 26
###begin p 27
###xml 176 189 176 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE-C1-C2-C4</italic>
###xml 328 330 328 330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP159C16">16</xref>
###xml 354 367 354 367 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE-C1-C2-C4</italic>
###xml 592 593 592 593 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP159F4">4</xref>
###xml 601 606 601 606 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE&#8211;</italic>
###xml 646 647 646 647 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 659 662 659 662 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;10</sup>
###xml 723 726 723 726 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cis</italic>
###xml 862 864 862 864 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP159C17">17</xref>
###xml 865 867 865 867 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP159C18">18</xref>
###xml 883 896 883 896 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE-C1-C2-C4</italic>
###xml 1021 1022 1021 1022 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1034 1037 1034 1037 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;14</sup>
###xml 1189 1202 1189 1202 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE-C1-C2-C4</italic>
###xml 1334 1335 1334 1335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP159F4">4</xref>
###xml 1342 1346 1342 1346 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CETP</italic>
###xml 1491 1492 1491 1492 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP159F4">4</xref>
###xml 1587 1589 1587 1589 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP159C19">19</xref>
SNPs in several other genes and regions, involved in lipid and lipoprotein transport or metabolism, appeared to exert more diverse phenotypic effects. For example, SNPs in the APOE-C1-C2-C4 cluster were associated with three lipid and lipoprotein traits (total- and LDL-cholesterol, apoB) consistent with previous observations (16). The phenome scan for APOE-C1-C2-C4 also revealed a strong association of SNPs in this region with the hepatocyte-derived inflammation marker C-reactive protein (CRP), but interestingly not with another hepatocyte-derived acute phase protein, fibrinogen (Fig. 4F). The APOE-CRP association was highly significant (P = 1.28 x 10-10) and the effect size was at least as large as the effect of cis-acting SNPs in the gene on CRP itself (). This association is also validated by several candidate gene studies and by two recent GWAS (17,18). In addition, APOE-C1-C2-C4 SNPs rs429358/rs7412, which together define the E2, E3 and E4 alleles, were also strongly associated with Lp-PLA2 activity (P = 2.55 x 10-14), and explained almost 4% of the variance in this trait, with a 0.21 SD difference in Lp-PLA2 activity between homozygous subjects. The association of APOE-C1-C2-C4 SNPs with apoAI was also evident but because of the more modest levels of significance, these associations are not shown in Figure 4F. The CETP SNP rs708272, which exhibited the strongest association with HDL-cholesterol in the genic scan, showed additional associations with apoAI (Fig. 4E). These associations have been corroborated by meta-analyses of genetic association studies (19).
###end p 27
###begin p 28
###xml 12 26 12 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOA5-A4-C3-A1</italic>
###xml 33 34 33 34 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP159F4">4</xref>
###xml 141 145 141 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LDLR</italic>
###xml 157 158 157 158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP159F4">4</xref>
###xml 170 175 170 175 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOA5</italic>
###xml 193 196 193 196 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LPL</italic>
###xml 255 257 255 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP159C20">20</xref>
###xml 281 286 281 286 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOA5</italic>
SNPs in the APOA5-A4-C3-A1 (Fig. 4A) cluster also exhibited diverse effects on blood lipid and lipoprotein phenotypes as did variants in the LDLR gene (Fig. 4B). For the APOA5 gene cluster and LPL, the anticipated association with triglycerides was seen (20). Furthermore, for the APOA5 cluster, although the previously reported association with apoAI was evident, with an FDR of 0.14 it was not included in the enlarged phenome scan where the FDR cut-off was 0.1.
###end p 28
###begin title 29
pQTSNPs as tools to distinguish causal from non-causal associations between blood protein phenotypes
###end title 29
###begin p 30
###xml 8 11 8 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cis</italic>
###xml 511 512 511 512 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP159F5">5</xref>
Because cis-acting variants in a gene encoding a protein trait (pQTSNPs) provide a highly specific instrument with which to investigate the causal effects of the encoded protein (utilizing the principles of Mendelian randomization), we used the most strongly associating pQTSNPs for apoAI, apoB, CRP, factor VII, fibrinogen and lipoprotein-associated phospholipase A2 (Lp-PLA2) as their unconfounded proxies to help evaluate confounding in the directly observed associations between these proteins () and (Fig. 5).
###end p 30
###begin p 31
###xml 365 366 365 366 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 376 377 376 377 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 386 387 386 387 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 395 396 395 396 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 423 424 423 424 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</bold>
###xml 443 444 443 444 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</bold>
The magnitude of the association between protein phenotypes is illustrated as the mean difference of the standardized levels of the phenotype between top and bottom tertile of the index phenotype, approximately equal to a 2 SD difference. When the most strongly associating SNP in the pQTGs is considered, the mean difference is between the two homozygote groups. (A) apoAI, (B) apoB, (C) CRP, (D) coagulation factor VII, (E) fibrinogen, and (F) Lp-PLA2.
###end p 31
###begin p 32
###xml 10 11 10 11 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP159F5">5</xref>
In Figure 5, the magnitude of the association between protein phenotypes is illustrated for a difference in the mean values of the top versus bottom tertile of the index phenotype, approximately equal to a 2 SD difference. Thus, a 2 SD difference in factor VII is associated with a standardized mean difference in apoB, CRP and fibrinogen of 0.41, 0.31 and 0.25, respectively. Individuals homozygous for the variant allele rs6046 exhibited a 2.15 SD higher blood factor VII level which is approximately equivalent to the difference in levels between the top and bottom tertile of the Factor VII distribution. However, the point estimate of the effect of rs6046 on levels of apoB and fibrinogen was null and therefore discordant from that expected from the directly observed association of factor VII with these phenotypes if this was a causal link. The point estimate of the association of rs6046 with CRP was close to that expected from a causal association, but the confidence limits spanned the null. Thus, the simplest explanation of these findings is that the factor VII is unlikely to cause an alteration in apoB or fibrinogen, but a causal effect on CRP is possible and would require a larger sample to confirm or refute reliably. For the majority of other pairwise comparisons, the point estimates of the genetic effect were either null or directionally opposite from that expected from a causal link, though because of wide confidence limits, larger studies would be required to provide definitive evidence.
###end p 32
###begin p 33
The relationship between minor allele frequency and standardized effect size for 80% statistical power is plotted in . The study can detect effects at 0.4 SD for any SNP with a MAF > 20%, but can only detect large effects (>0.8SD) from a SNP with <10% MAF.
###end p 33
###begin title 34
DISCUSSION
###end title 34
###begin title 35
Gene centric (genic scan) to identify variants influencing multiple blood biomarkers
###end title 35
###begin p 36
###xml 725 727 713 715 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP159C11">11</xref>
###xml 746 747 734 735 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP159C8">8</xref>
###xml 786 787 774 775 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP159C5">5</xref>
###xml 788 789 776 777 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP159C6">6</xref>
###xml 815 817 803 805 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP159C21">21</xref>
###xml 1399 1445 1387 1433 <uri xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:type="simple" xlink:href="http://bioinf.itmat.upenn.edu/cvdsnp/index.php">http://bioinf.itmat.upenn.edu/cvdsnp/index.php</uri>
###xml 1448 1450 1436 1438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP159C22">22</xref>
We developed a genotyping strategy aimed at providing a suite of tools to help evaluate the nature of associations between multiple blood markers associated with a high risk of CHD using Mendelian randomization. We used a gene-centric approach based on genes with a high prior probability of association with the traits of interest in NPHSII. This proved to be an efficient strategy providing a high yield of SNP-biomarker associations even at conservative levels of statistical significance and a stringent FDR threshold, with134 SNP-associations out of the 948 SNPs ( for which genotype was available), distributed among approximately36 genes. These findings are in keeping with emerging data from GWAS of gene expression (11), blood proteins (8), lipid and other non-protein traits (5,6) and metabolic profiles (21). Together these provide strong evidence that regulatory SNPs are found commonly in the vicinity of genes and validate a gene-centric approach to identify genotypes influencing multiple blood traits linked to CHD and other complex disorders. The scope and breadth of gene-centric studies is likely to be extended by the emergence of comprehensive disease-specific gene-centric custom SNP arrays such as the ITMAT/BROAD/CARE (IBC) 'cardio-metabolic chip' that covers around 2100 genes from lipid, inflammation, coagulation, oxidants stress, matrix and other pathways linked to CHD (http://bioinf.itmat.upenn.edu/cvdsnp/index.php) (22).
###end p 36
###begin p 37
###xml 132 136 132 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 369 382 369 382 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE-C1-C2-C4</italic>
###xml 619 623 619 623 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOB</italic>
###xml 629 633 629 633 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LDLR</italic>
Although the genotyping strategy was focused on candidate genes, some novel associations also emerged, e.g. associations of SNPs in APOE with Lp-PLA2 activity. Lp-PLA2 is physically associated with LDL particles where it could exert pro-atherogenic actions through hydrolysis of oxidized phospholipids to lysophosphatidylcholine and oxidized free fatty acids. Although APOE-C1-C2-C4 SNPs also influence the level of circulating LDL, and theoretically might therefore influence Lp-PLA2 activity simply through an effect on the concentration of this particle, other SNPs that affected LDL-cholesterol concentration (e.g. APOB, and LDLR) were not associated with Lp-PLA2 activity, suggesting a more direct link between apoE and Lp-PLA2 that is worthy of further investigation.
###end p 37
###begin p 38
###xml 337 338 337 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP159C9">9</xref>
###xml 1045 1046 1045 1046 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP159C4">4</xref>
###xml 1279 1284 1279 1284 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HMGCR</italic>
###xml 1448 1450 1448 1450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP159C23">23</xref>
###xml 1537 1539 1537 1539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP159C24">24</xref>
Though 16 of the genetic associations we identified have been corroborated by both candidate gene studies and GWAS, and can be considered robust, the relevance and utility of such associations has been debated given that the proportion of the total variance in a continuous trait explained by common alleles can be small (commonly <5%) (9). However, our study suggests that interpretations based on this metric alone may provide an incomplete picture. For many SNPs whose contribution to the variance in a phenotype was small, we found evidence of a substantial effect size when expressed in terms of the standardized mean difference in biomarker level between homozygous subjects. We noted many examples of differences over 0.5 SD, and several of over 1 SD for variants influencing triglycerides, apoB, Lp-PLA2 and factor VII. These would be considered very substantial effects for a drug designed to modify the level of one of these biomarkers. For example, standard doses of statin drugs in clinical use reduce LDL-cholesterol by about 1 SD (4). However, even SNPs with small effect could be important, because therapies that might arise from the genetic findings could be designed to have much more potent effects than the natural genetic variation. For example, variants in HMGCR that encodes the target enzyme for cholesterol-lowering statin drugs, affect LDL-cholesterol but did not emerge among the top-ranking SNPs in recent GWAS for CHD (23), although an association of these SNPs with CHD risk has been subsequently reported (24).
###end p 38
###begin p 39
###xml 178 179 178 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP159F3">3</xref>
###xml 303 305 303 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP159C25">25</xref>
We also noted a trend for less common genetic variants to exert larger effects when expressed in terms of the standardized mean difference but not in terms of the variance (Fig. 3). This finding is consistent with the emerging paradigm of an inverse association between allele frequency and penetrance (25).
###end p 39
###begin title 40
Phenome scans and use of SNPs as tools to distinguish causal from confounded links between biomarkers
###end title 40
###begin p 41
###xml 461 463 461 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP159C26">26</xref>
It has been common for genome wide and candidate gene association studies to focus on SNP associations with a single trait or disease outcome, but the pathway from disease-relevant SNP to disease potentially involves multiple phenotypic perturbations both in series and in parallel. It is therefore of interest not only to determine the full spectrum of SNPs affecting a single trait or outcome, but also the range of phenotypes altered by single SNP or gene. (26). We noted several genes and SNPs with effects on multiple circulating biomarkers, suggesting that some genes may have a broad footprint of effects on the proteome and metabolome. This is often referred to as pleiotropy but it may be important to distinguish between the multiplicity of effects arising from the generation of more than one protein product as a result of alternative splicing of an mRNA transcript of a gene, from the those arising from the broad ranging downstream effects of a single protein product (such as an enzyme or transporter) involved in lipid and lipoprotein pathways (e.g. apoE or cholesteryl ester transfer protein), which is the more likely explanation for the range of SNP effects observed in the present study.
###end p 41
###begin p 42
###xml 86 88 86 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F7</italic>
###xml 93 96 93 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FIB</italic>
###xml 526 527 526 527 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP159F1">1</xref>
###xml 530 532 530 532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP159C27">27</xref>
###xml 533 535 533 535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP159C28">28</xref>
###xml 842 844 842 844 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP159C29">29</xref>
###xml 845 847 845 847 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP159C31">31</xref>
Though some SNPs exerted a broad footprint of phenotypic effects, for others (e.g. in F7 and FIB), there was a more tightly restricted association of SNPs in the encoding gene with the cognate protein but no other trait, despite the extensive directly observed correlations between the protein itself and other markers. This contrast between the range of genotypic and phenotypic associations is likely to arise from the randomized assignment of alleles, and the non-randomized (clustered) association of phenotypes (see Fig. 1) (27,28). This renders SNPs in certain pQTGs particularly well suited as proxies (instruments) with which to investigate the causal relevance for CHD of the proteins they encode because, in contrast to the proteins themselves, the genetic associations should not be prone to confounding or reverse causation bias (29-31).
###end p 42
###begin p 43
###xml 57 58 57 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">R</italic>
###xml 58 59 58 59 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 73 74 73 74 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP159F1">1</xref>
###xml 773 776 773 776 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CRP</italic>
###xml 808 816 808 816 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FIBA-B-G</italic>
###xml 839 840 839 840 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP159F4">4</xref>
###xml 920 922 920 922 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP159C29">29</xref>
###xml 923 925 923 925 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP159C32">32</xref>
For example, CRP is strongly correlated with fibrinogen (R2 = 0.43; Fig. 1). This association could arise because of a causal relationship (in either direction) or because of a common association of both these biomarkers with another factor. This makes it difficult to assess whether CRP and fibrinogen lie on the same causal pathway to CHD, and whether it is legitimate to make statistical adjustment for fibrinogen in the many observational associations of CRP with CHD (and vice versa). Statistical adjustment, which is the orthodox approach to dealing with confounding in observational epidemiology, would be legitimate only if the association of CRP with CHD was not mediated (even in part) by an elevation in the level of fibrinogen. The absence of an association of CRP SNPs with fibrinogen level (or FIBA-B-G with CRP level) (Fig. 4I), which is consistent with the findings from other studies of these variants (29,32) indicates that CRP and fibrinogen do not exhibit a direct causal association with one another and that statistical adjustment is appropriate in observational studies of these biomarkers with CHD.
###end p 43
###begin p 44
###xml 8 11 8 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cis</italic>
Whereas cis-acting SNPs in the encoding gene offer the most specific genetic instrument with which to assess the causal role of a protein in CHD, there may not be a single best instrument for a non-protein trait such as the level of HDL- or LDL-cholesterol that are influenced by a number of different genes encoding enzymes and transporters. We noted SNPs from a range of genes influencing the same lipid trait (). Validation of the use of multiple SNPs for such causal analysis for non-protein traits is illustrated using the example of LDL-cholesterol, the only blood phenotype for which a causal role in CHD has already been firmly established.
###end p 44
###begin p 45
###xml 17 21 17 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LDLR</italic>
###xml 23 27 23 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOB</italic>
###xml 62 67 62 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 154 156 154 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP159C33">33</xref>
###xml 165 170 165 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 276 278 276 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP159C34">34</xref>
###xml 313 317 313 317 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 319 321 319 321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP159C16">16</xref>
###xml 324 349 324 349 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PSRC1/ CELSR/ SORT1, LDLR</italic>
###xml 354 359 354 359 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 361 362 361 362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP159C5">5</xref>
###xml 363 364 363 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP159C7">7</xref>
###xml 365 367 365 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP159C35">35</xref>
###xml 531 532 531 532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP159C5">5</xref>
###xml 533 535 533 535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP159C34">34</xref>
###xml 536 538 536 538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP159C35">35</xref>
Rare variants in LDLR, APOB and gain-of-function mutations in PCSK9 result in extreme elevations in LDL-cholesterol, as in Familial Hypercholesterolemia (33), while PCSK9 loss-of-function variants are associated with very low LDL-cholesterol levels and are protective of CHD (34). In addition, common variants of APOE (16), PSRC1/ CELSR/ SORT1, LDLR and PCSK9 (5-7,35), including some tagged by SNPs in the current study that cause more modest changes in LDL-cholesterol, have also been associated with alterations in risk of CHD (5,34,35), with the genetic effects on disease risk directionally concordant and in proportion to the size of the effect on LDL-cholesterol.
###end p 45
###begin title 46
Implications of the current findings for future work
###end title 46
###begin p 47
###xml 873 875 873 875 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP159C36">36</xref>
The principles applied in the current study could be extended to incorporate rare SNPs or copy number variants, or regulatory SNPs remote from genes using denser new generation GWAS platforms. The phenotypes evaluated could be extended both proximally to include mRNA expression and more distally to include more complex phenotypes linked to CHD such as carotid-intima media thickness or measures of coronary artery calcification. The breadth of the approach could also be extended laterally at the level of protein and non-protein phenotypes using proteomic and metabolomics, respectively. Our study highlights the importance of well-phenotyped population samples and emphasizes the requirement for large sample sizes. However, whether this approach will aid in developing causal networks and genotype: phenotype maps, as outlined recently by Rockman, remains to be seen (36).
###end p 47
###begin p 48
###xml 91 97 <span type="species:ncbi:9606">humans</span>
In summary, we demonstrate how integrating information on genotype and blood phenotypes in humans can be used to construct association networks with a high-level of credibility, due to the particular properties of genetic variants, which are randomly allocated and unmodifiable by disease process, features which are not shared by any other natural biological exposure (e.g. mRNA levels or protein levels) Our study emphasizes the potential translational application emerging from the recent genomic advances.
###end p 48
###begin title 49
MATERIAL AND METHODS
###end title 49
###begin title 50
Study design and phenotypic measures
###end title 50
###begin p 51
###xml 193 195 193 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP159C37">37</xref>
###xml 1073 1075 1073 1075 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP159C37">37</xref>
###xml 94 97 <span type="species:ncbi:9606">men</span>
###xml 198 201 <span type="species:ncbi:9606">Men</span>
###xml 758 761 <span type="species:ncbi:9606">men</span>
The Northwick Park Heart Study II (NPHSII) is a prospective study of 3012 healthy middle-aged men aged 50-64 years at recruitment, sampled from nine UK general practices between 1989 and 1994 (37). Men were free from disease at the time of recruitment, and information on lifestyle habits, height, weight and blood pressure were recorded at baseline and on subsequent prospective follow-up. Measures were made of at least 15 circulating blood factors associated with CHD risk that included both circulating proteins (CRP, lipid fractions and non-protein metabolites), all the measures being obtained before the development of clinical events, with repeated measurements available for some factors (). A DNA repository was established using samples from 2775 men obtained at the time of recruitment. By December 2005, after a median follow-up of 13.6 years, there had been 296 definite fatal or non-fatal CHD events (230 in 2401 of the genotyped sample). Full details of recruitment, measurements, follow-up and definitions of incident disease have been reported elsewhere (37).
###end p 51
###begin title 52
Genic scan
###end title 52
###begin p 53
###xml 143 144 143 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP159C1">1</xref>
###xml 337 338 337 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP159C2">2</xref>
###xml 521 522 521 522 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 527 529 527 529 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;7</sup>
###xml 635 636 635 636 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP159C3">3</xref>
###xml 686 688 686 688 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP159C38">38</xref>
###xml 810 811 810 811 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">R</italic>
###xml 811 812 811 812 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
A customized Illumina 768 SNP genotyping array was assembled to comprehensively capture common genetic variation in more than 76 genes chosen (1): for their involvement in the following pathways linked to CHD risk; lipid metabolism (10 genes), inflammation (23 genes), oxidative stress (13 genes), thrombosis and haemostasis (3 genes); (2) for a previously described association with the risk of CHD or type 2 diabetes (T2D) mellitus, including SNPs from a recent whole-genome analysis of T2D which marginally failed the P < 10-7 significance threshold for genome wide significance (Prof Philippe Froguel, personal communication); or (3) for their ability to tag copy number variation (38). For each gene or region, tagging (t) SNPs, optimized for the Illumina platform, was selected using HapMap, applying an R2 threshold of 0.8 with a minor allele frequency threshold of 0.04. Where possible, coding (c) SNPs were included in the tag set. Illumina Goldengate SNPs with pre-optimized assays were chosen where possible, however roughly 10% of the chosen SNPs failed the assay design. A complete list of genes selected and the tSNPs for each gene for which genotype was available is shown in . Genotypes from the Illumina array were supplemented with information on 173 SNPs in a further 82 genes previously typed in this data set (). SNPs were examined for associations with 12 blood phenotypes available in NPHSII of which six were protein phenotypes (CRP, fibrinogen, apoAI, apoB, Lp-PLA2 and factor VII) and six were non-protein metabolic phenotypes (total-cholesterol, HDL- and calculated LDL-cholesterol, triglycerides, homocysteine and folate). We refer to this as a genic scan to distinguish the focused high SNP density, gene-centric approach used here from broader, generally lower SNP density, genome-wide analyses.
###end p 53
###begin title 54
Phenome scan
###end title 54
###begin p 55
###xml 206 216 206 216 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vide infra</italic>
###xml 380 390 380 390 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vide infra</italic>
We examined the effect of the genes containing the highest ranking SNPs from the genic scan on additional blood biomarkers beyond the index trait and the results are illustrated by means of a phenome plot (vide infra). These findings are summarized by means of phenome plots that summarize the associations of SNPs in a gene with blood marker(s) both in terms of the FDR q-value (vide infra) and proportion of the variance of the trait explained, using a stepwise regression to find the adjusted coefficient of determination (adjR2) under the model of best fit.
###end p 55
###begin title 56
Statistical analysis
###end title 56
###begin p 57
###xml 732 733 732 733 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 804 806 804 806 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP159C39">39</xref>
###xml 924 925 924 925 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 955 957 955 957 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP159C40">40</xref>
###xml 1242 1243 1242 1243 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">R</italic>
###xml 1243 1244 1243 1244 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1414 1456 1414 1456 <uri xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:type="simple" xlink:href="http://pngu.mgh.harvard.edu/purcell/plink/">http://pngu.mgh.harvard.edu/purcell/plink/</uri>
###xml 1458 1460 1458 1460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP159C41">41</xref>
###xml 1489 1490 1489 1490 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">R</italic>
###xml 1490 1491 1490 1491 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
Phenotypes were tested for deviation from the normal and transformed where appropriate, using the Box-Cox transformation. Pair-wise linear relationships between blood phenotypes were tested using Pearson correlation. If the phenotypic variant was measured once in the study, an ANOVA was used to test for its association with genotype. Where multiple measurements were available, the average value of the available measurements was calculated and a general linear model was fitted through the data using indicator variables. The regression coefficients obtained for the indicator variables compared to the reference category were assessed for significance using a Wald test. Based on the number of hypotheses tested, a FDR adjusted P-value was calculated using the methodology of Benjamini and Hochberg (39). Defining FDR as the proportion of falsely rejected hypotheses, i.e. for which the null was actually true, this new P-value, known as the q-value (40), is the minimum FDR when rejecting a null hypothesis from a list of tested null hypothesis, conditioned on at least one positive finding having occurred. For the construction of the phenomic plots, a stepwise regression was used to find the adjusted coefficient of determination (adjR2) under the model of best fit. The number of independent loci associated with each phenotype was calculated using the LD-based result clumping procedure in PLINK (v1.05, http://pngu.mgh.harvard.edu/purcell/plink/ (41). An extremely conservative R2 of 0.1% was used to clump SNPs, identified previously as statistically significant, in independent loci.
###end p 57
###begin title 58
SUPPLEMENTARY MATERIAL
###end title 58
###begin p 59
.
###end p 59
###begin p 60
###xml 0 30 0 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Conflict of Interest statement</italic>
Conflict of Interest statement. None declared.
###end p 60
###begin title 61
FUNDING
###end title 61
###begin p 62
###xml 31 55 31 55 <grant-sponsor xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">British Heart Foundation</grant-sponsor>
###xml 70 80 70 80 <grant-num xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PG2005/014</grant-num>
###xml 147 157 147 157 <grant-num xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FS2005/125</grant-num>
This work was supported by the British Heart Foundation (grant number PG2005/014; F.D., P.J.T., J.P. and S.E.H. and a Senior Fellowship to A.D.H., FS2005/125). Funding to pay the Open Access charge was provided by the British Heart Foundation.
###end p 62
###begin title 63
Supplementary Material
###end title 63
###begin title 64
[Supplementary Data]
###end title 64
###begin title 65
REFERENCES
###end title 65
###begin article-title 66
Translating molecular discoveries into new therapies for atherosclerosis
###end article-title 66
###begin article-title 67
A survey of 246 suggested coronary risk factors
###end article-title 67
###begin article-title 68
In search of fewer independent risk factors
###end article-title 68
###begin article-title 69
###xml 101 113 <span type="species:ncbi:9606">participants</span>
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins
###end article-title 69
###begin article-title 70
Newly identified loci that influence lipid concentrations and risk of coronary artery disease
###end article-title 70
###begin article-title 71
Genome-wide association study identifies genes for biomarkers of cardiovascular disease: serum urate and dyslipidemia
###end article-title 71
###begin article-title 72
LDL-cholesterol concentrations: a genome-wide association study
###end article-title 72
###begin article-title 73
A genome-wide association study identifies protein quantitative trait loci (pQTLs)
###end article-title 73
###begin article-title 74
Nature's randomised trials
###end article-title 74
###begin article-title 75
Strengthening causal inference in cardiovascular epidemiology through Mendelian randomization
###end article-title 75
###begin article-title 76
###xml 45 50 <span type="species:ncbi:9606">human</span>
Genetic analysis of genome-wide variation in human gene expression
###end article-title 76
###begin article-title 77
###xml 24 29 <span type="species:ncbi:9606">human</span>
Mapping determinants of human gene expression by regional and genome-wide association
###end article-title 77
###begin article-title 78
Relative impact of nucleotide and copy number variation on gene expression phenotypes
###end article-title 78
###begin article-title 79
Bayesian meta-analysis of genetic association studies with different sets of markers
###end article-title 79
###begin article-title 80
###xml 129 135 <span type="species:ncbi:9606">humans</span>
Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans
###end article-title 80
###begin article-title 81
Association of apolipoprotein E genotypes with lipid levels and coronary risk
###end article-title 81
###begin article-title 82
###xml 128 133 <span type="species:ncbi:9606">Women</span>
Loci related to metabolic-syndrome pathways including LEPR, HNF1A, IL6R, and GCKR associate with plasma C-reactive protein: the Women's Genome Health Study
###end article-title 82
###begin article-title 83
Genome-wide linkage analysis for circulating levels of adipokines and C-reactive protein in the Quebec family study (QFS)
###end article-title 83
###begin article-title 84
Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk
###end article-title 84
###begin article-title 85
Relative contribution of variation within the APOC3-A4-A5 gene cluster in determining plasma triglycerides
###end article-title 85
###begin article-title 86
###xml 87 92 <span type="species:ncbi:9606">human</span>
Genetics meets metabolomics: a genome-wide association study of metabolite profiles in human serum
###end article-title 86
###begin article-title 87
Concept, design and implementation of a cardiovascular gene-centric 50 k SNP array for large-scale genomic association studies
###end article-title 87
###begin article-title 88
Genomewide association analysis of coronary artery disease
###end article-title 88
###begin article-title 89
Polymorphisms associated with cholesterol and risk of cardiovascular events
###end article-title 89
###begin article-title 90
Common and rare variants in multifactorial susceptibility to common diseases
###end article-title 90
###begin article-title 91
The search for genenotype/phenotype associations and the phenome scan
###end article-title 91
###begin article-title 92
Alcohol intake and blood pressure: a systematic review implementing a Mendelian randomization approach
###end article-title 92
###begin article-title 93
Clustered environments and randomized genes: a fundamental distinction between conventional and genetic epidemiology
###end article-title 93
###begin article-title 94
Insight into the nature of the CRP-coronary event association using Mendelian randomization
###end article-title 94
###begin article-title 95
Does elevated plasma fibrinogen increase the risk of coronary heart disease? Evidence from a meta-analysis of genetic association studies
###end article-title 95
###begin article-title 96
Fibrinogen and coronary heart disease: test of causality by 'Mendelian randomization
###end article-title 96
###begin article-title 97
Association of C-reactive protein with blood pressure and hypertension: life course confounding and mendelian randomization tests of causality
###end article-title 97
###begin article-title 98
###xml 26 34 <span type="species:ncbi:9606">patients</span>
Mutational analysis in UK patients with a clinical diagnosis of familial hypercholesterolaemia: relationship with plasma lipid traits, heart disease risk and utility in relative tracing
###end article-title 98
###begin article-title 99
Sequence variations in PCSK9, low LDL, and protection against coronary heart disease
###end article-title 99
###begin article-title 100
Lifelong reduction of LDL-cholesterol related to a common variant in the LDL-receptor gene decreases the risk of coronary artery disease-a Mendelian Randomisation study
###end article-title 100
###begin article-title 101
Reverse engineering the genotype-phenotype map with natural genetic variation
###end article-title 101
###begin article-title 102
Comparison of novel hemostatic factors and conventional risk factors for prediction of coronary heart disease
###end article-title 102
###begin article-title 103
###xml 39 44 <span type="species:ncbi:9606">human</span>
Global variation in copy number in the human genome
###end article-title 103
###begin article-title 104
Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society B 57: 289-300
###end article-title 104
###begin article-title 105
A direct approach to false discovery rates
###end article-title 105
###begin article-title 106
PLINK: a tool set for whole-genome association and population-based linkage analyses
###end article-title 106
###begin article-title 107
Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease
###end article-title 107
###begin article-title 108
Sorl1 as an Alzheimer's disease predisposition gene?
###end article-title 108

